scholarly journals Association between peroxisome proliferator-activated receptor-alpha, delta, and gamma polymorphisms and risk of coronary heart disease

Medicine ◽  
2017 ◽  
Vol 96 (2) ◽  
pp. e5949
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Receptor Alpha

scholarly journals Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus

2002 ◽  
pp. 545-551 ◽  
Author(s):  
M Bluher ◽  
T Klemm ◽  
T Gerike ◽  
H Krankenberg ◽  
G Schuler ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Multiple Logistic Regression Analysis ◽  
Peroxisome Proliferator ◽  
Haemoglobin A1c ◽  
Peroxisome Proliferator Activated Receptor ◽  
Patients With Diabetes ◽  
Reduced Risk

OBJECTIVE: Recent evidence indicates that peroxisome proliferator-activated receptor-gamma (PPARgamma) is expressed at high levels in foam cells of atherosclerotic lesions, that PPARgamma agonists may directly modulate vessel wall function and that mutations in the PPARgamma-2 gene are associated with a reduced risk of coronary artery disease. METHODS: We investigated whether known variants in the PPARgamma-2 gene are associated with the occurrence of coronary heart disease (CHD) in 365 patients with type 2 diabetes, prospectively characterised for the presence or absence of CHD. The Pro115Gln, Pro12Ala, Pro467Leu, Val290Met mutations and two polymorphisms C478T and C161T of the PPARgamma-2 gene were examined using PCR, denaturing gradient gel electrophoresis and direct sequencing. RESULTS: The distribution of the Pro12Ala, Ala12Ala, C161T and T161T variants was not significantly different between patients with and without CHD, independent of the gender. The Pro12Ala (P=0.011) and the Ala12Ala (P=0.006) variant were associated with a higher body mass index (BMI) compared with the Pro12Pro genotype. A multiple logistic regression analysis introducing the typical risk factors for CHD (age, sex, hypertension, smoking, BMI >26 kg/m2, elevated low density lipoprotein cholesterol and haemoglobin A1c >7%) identified age >60, male gender, hypertension and a higher BMI, but not the PPARgamma-2 variants, as significant risk factors for CHD in our study groups. CONCLUSION: The PPARgamma-2 genotype was not associated with an increased or reduced risk of the occurrence of CHD and can therefore not be regarded as an independent risk factor for CHD in patients with diabetes mellitus.

Peroxisome proliferator-activated receptor (PPAR) isoforms in coronary heart disease

2013 ◽  
Vol 38 (4) ◽  
pp. 372-384
Author(s):  
Hulya Yilmaz Aydogan ◽  
Ozlem Kurt ◽  
Ozlem Kurnaz ◽  
Basak Akadam Teker ◽  
Ozlem Kucukhuseyin
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor

scholarly journals Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease

PPAR Research ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-11 ◽  
Author(s):  
Jean Dallongeville ◽  
Carlos Iribarren ◽  
Jean Ferrières ◽  
Liisa Lyon ◽  
Alun Evans ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Association Studies ◽  
Meta Analysis ◽  
Recessive Model ◽  
Peroxisome Proliferator ◽  
Nucleotide Polymorphisms ◽  
Peroxisome Proliferator Activated Receptor ◽  
Chd Risk ◽  
Obesity And Diabetes

Single nucleotide polymorphisms (SNPs) in the peroxisome proliferator-activated receptorγ(PPARG) gene have been associated with cardiovascular risk factors, particularly obesity and diabetes. We assessed the relationship between 4PPARGSNPs (C-681G, C-689T, Pro12Ala, and C1431T) and coronary heart disease (CHD) in the PRIME (249 cases/494 controls, only men) and ADVANCE (1,076 cases/805 controls, men or women) studies. In PRIME, homozygote individuals for the minor allele of thePPARGC-689T, Pro12Ala, and C1431T SNPs tended to have a higher risk of CHD than homozygote individuals for the frequent allele (adjusted OR [95% CI] = 3.43 [0.96–12.27],P=.058, 3.41 [0.95–12.22],P=.060and 5.10 [0.99–26.37],P=.050, resp.). No such association could be detected in ADVANCE. Haplotype distributions were similar in cases and control in both studies. A meta-analysis on the Pro12Ala SNP, based on our data and 11 other published association studies (6,898 CHD cases/11,287 controls), revealed that there was no evidence for a significant association under the dominant model (OR=0.99[0.92–1.07],P=.82). However, there was a borderline association under the recessive model (OR=1.29[0.99–1.67],P=.06) that became significant when considering men only (OR=1.73[1.20–2.48],P=.003). In conclusion, thePPARGAla12Ala genotype might be associated with a higher CHD risk in men but further confirmation studies are needed.

Sign in / Sign up

Export Citation Format

Share Document